Status:
UNKNOWN
Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
Lead Sponsor:
Rabin Medical Center
Collaborating Sponsors:
Tel-Aviv Sourasky Medical Center
Soroka University Medical Center
Conditions:
Lymphoma
Neutropenia
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
Granulocyte colony stimulating factors (GCSFs) stimulate the level of white blood cells, specifically neutrophils. GCSF support for patients receiving chemotherapy was shown to decrease the rate of fe...
Eligibility Criteria
Inclusion
- Adult patients (age 18 years or above)
- Refractory or relapsed aggressive lymphoma, including Hodgkin's and non-Hodgkin's lymphoma
- Candidate for salvage chemotherapy. Salvage chemotherapy includes one of the following regimens: Ifosfamide, etoposide, vincristine (ICE), Cisplatin, cytarabine, and dexamethasone (DHAP), Etoposide, methylprednisolone, cytarabine, cisplatin (ESHAP). Chemotherapy dose reduction will be allowed.
- Chemotherapy with or without immunotherapy
- Therapy in hospital or at the outpatient clinic
Exclusion
- Indolent lymphoma; we will exclude patients with transformed lymphoma.
- Treatment with GCSFs for the primary disease (e.g. aplastic anemia, MDS).
- Uncontrolled infection
- Pregnant women
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT02238873
Start Date
October 1 2014
Last Update
October 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petah Tikva, Israel, 49100